Search
Congratulations to Luke Timmerman on 10 years of Timmerman Report. We salute you!
Celebrating with the Seattle (and beyond) biotech community.
Mar 13
Tour of Scotland: Glasgow based EnteroBiotix is developing microbiome based treatments using a 'full ecosystem' of strains you would expect to see in a healthy microbiome
CEO James McIlroy describes the scientific platform and how it contrasts to other microbiome approaches. A trial in IBS is scheduled to...
Mar 13
Tour of Scotland: Scotland's Chief Scientist (Health) describes how new technologies are being embraced in the NHS, and why Scotland is a good place for global companies to run clinical trials
Professor Dame Anna Dominiczak describes how new technologies are being rolled out in the community equitably, such as digital...
Mar 13
HumanX: Generate Biomedicines' CEO Mike Nally describes how he sees AI going from improvements in optimization to drugging the undruggable
From the big HumanX AI conference in Las Vegas, he describes the overall path he sees AI taking in its contributions to drug development,...
Mar 13
Tour of Scotland: St. Andrews based Pneumagen aims to prevent viral respiratory infections with an intra-nasally delivered platform that harnesses glycan targeted Carbohydrate Binding Module domains
Co-Founder & CEO Douglas Thomson describes how the company was founded, and walks us through the science. Plus, a recap of recently...
Mar 13
Tour of Scotland: Dundee based Glen Clova Scientific is using virus-like particles to lower levels of cytokines in patients experiencing chronic inflammatory conditions
CEO Steven Powell joins BiotechTV from Scotland's Life Sciences Conference and Awards in Glasgow, and explains Glen Clova's expertise in...
Mar 13
Tour of Scotland: Mark Cook, Co-Chair of Life Sciences Scotland, describes the importance of life sciences to the area and what the government and industry are doing to support it
He describes the assets that Scotland has to offer the industry such as excellent universities that derive innovation and a diverse...
Mar 13
Tour of Scotland: Glasgow based Mironid is developing a small molecule to directly target aberrantly high cAMP that causes Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Co-Founder & CEO Neil Wilkie walks us through the biology of ADPKD and explains how Mironid is trying to uniquely directly target it....
Mar 13
Tour of Scotland: Vicki Hazley, Associate Director of The Scottish National Investment Bank, discusses how The Bank invests in life sciences
She describes The Bank's goal of supporting life sciences in Scotland and making a societal impact, how it aims to co-invest with...
Mar 13
Professor Pieter Cullis and Jay Kulkarni, co-founders of NanoVation Therapeutics, discusses the next generation of lipid nanoparticle delivery
Professor Cullis, one of the original pioneers of LNPs and co-founder of 11 biotechnology companies, describes the challenge of...
Mar 12
Tour of Scotland: Edinburgh based Trogenix is developing an AAV based gene therapy platform for cancer that is designed to deliver combination immune payloads to the tumor
CEO Ken Macnamara describes the science behind this idea and discusses recently presented preclinical data. He highlights the lead...
Mar 12
Tour of Scotland: A leading investor who is focused on life sciences in Scotland shares his thoughts on the innovation happening in the area
Andrew McNeill, Managing Partner of St. Andrews based Eos Advisory, introduces us to the firm and some portfolio companies including...
Mar 12
Acuitas Therapeutics is a pioneer in developing lipid nanoparticles, and already has seen two approved products: ONPATTRO and the Pfizer/BioNTech mRNA vaccine
Co-Founder & CEO Thomas Madden describes the science and history behind LNPs, and discusses what is currently in development, including...
Mar 12
Tour of Scotland: Edinburgh based Cumulus Oncology has built a hub and spoke model of creating multiple spin-out companies - it already has three disclosed assets
Founder & CEO Clare Wareing describes the company's design, with an eye towards being capital efficient and investing over and again for...
Mar 12
Tour of Scotland: Outrun Therapeutics is aiming to create a new category of therapeutics by stabilizing proteins via drugging E3 ligases
CEO Carolyn Porter describes the beginning of the company, which spun out of University of Dundee's MRC Protein Phosphorylation and...
Mar 11
Tour of Scotland: Tay Therapeutics is a product of University of Dundee's Drug Discovery Unit, and is working on small molecules - including a topical pan-BET that is in phase 2
Founder and CEO Andrew Woodland describes how they made the decision to focus on inflammation for the pan-BET, which is partnered with...
Mar 11
Tour of Scotland: University of Dundee has established a world-class Centre for Protein Degradation, one of the hottest emerging modalities in biotech
Founder and Director Alessio Ciulli explains the science behind protein degradation. He then describes the facilities that have been...
Mar 11
Tour of Scotland: The Head of Business Development at University of Dundee's Drug Discovery Unit talks about how the university helps biopharma companies translate science into medicines
Charlotte Green describes the work that the unit does in tropical diseases, CNS, women's health, and oncology. She also highlights their...
Mar 11
Tour of Scotland: Sir Michael Ferguson introduces the work in life sciences that has built up at The University of Dundee and the specialized centers that have come from it
He discusses speciality work relating to molecular cell biology / signal transduction, and translational science. Plus, the MRC Protein...
Mar 11
Introducing The Savills Studio, a great space in the Prudential Tower that is home to the Boston life sciences team, and is available for clients and future clients to use for work or events
Reach out to learn more about how this expert team can help you find and build out your lab space. Featuring: Chris Gorczyca | Corporate...
Mar 10
.png){kind=logo}
